NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

抗生素:技術/全球市場

Antibiotics: Technologies and Global Markets

出版商 BCC Research 商品編碼 980078
出版日期 內容資訊 英文 170 Pages
訂單完成後即時交付
價格
抗生素:技術/全球市場 Antibiotics: Technologies and Global Markets
出版日期: 2020年12月28日內容資訊: 英文 170 Pages
簡介

全球抗生素市場預計將從2020年的444億美元增長到2025年的654億美元,從2020年到2025年的複合年增長率為8.1%。

細胞壁抑制劑市場預計將從2020年的234億美元增長到2025年的351億美元,從2020年到2025年的複合年增長率為8.4%。

蛋白質抑制劑領域預計將從2020年的136億美元增長到2025年的202億美元,從2020年到2025年的複合年增長率為8.3%。

本報告研究和分析了全球抗生素市場,並提供了有關市場概況,市場動態,市場細分,主要公司等的系統信息。

目錄

第1章簡介

第2章摘要和重點

第3章市場/技術背景

  • 抗生素概述
  • 抗生素常見的副作用
  • 抗生素分類
  • 細胞壁抑制劑
  • 蛋白抑制劑
  • DNA抑制劑
  • 其他抗生素類別
  • 革蘭氏陰性菌和革蘭氏陽性菌概述
  • 管理途徑
  • 抗生素市場趨勢
  • 為新抗生素開發提供資金
  • 小型製藥公司越來越重視抗生素開發
  • 擴大公私夥伴關係

第4章市場動態

  • 市場促進因素
  • 抗生素推動全球製藥市場增長
  • 老年人口和感染率增加
  • 院內感染髮生率增加
  • 提高對疾病及其抗生素的認識
  • 市場抑制因素
  • 抗生素耐藥性感染
  • 抗生素和藥物的通用化
  • 研發投入減少
  • 抗生素的副作用
  • 市場機會
  • 向新興國家市場擴展
  • 開發新的抗菌藥物

第5章市場細分:按產品

  • 全球抗生素市場:按產品
  • 細胞壁抑製劑
  • 蛋白抑製劑
  • DNA抑製劑
  • 其他

第6章市場細分:按管理途徑

  • 全球抗生素市場:按管理途徑
  • 口服
  • 局部
  • 其他

第7章市場細分:按地區

  • 全球抗生素市場:按地區
  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第8章COVID-19對製藥行業的影響

  • 短期影響
  • 需求變化
  • 將溝通和推廣轉移到遠程
  • 研究與開發的變化
  • 長期影響
  • 與COVID無關的藥物的延遲批准
  • 製藥業的自給自足
  • 製藥業增長放緩
  • 與健康有關的產品的消費趨勢變化

第9章臨床開發和管道產品

  • 呼吸道感染

第10章價值鏈分析

  • 簡介
  • 中國成為微生物威脅的中心

第11章管制方案

  • FDA/國際法規
  • 最近的監管改革
  • Ketek案例研究

第12章競爭情況

  • 全球公司的市場份額分析
  • 合併,聯盟,合夥,收購

第13章公司簡介

  • ABBOTT
  • F. HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • JOHNSON & JOHNSON
  • MERCK & CO., INC.
  • MYLAN N.V.
  • PFIZER INC.
  • SANOFI

第14章附錄:縮寫

目錄
Product Code: PHM025E

Highlights:

The global market for antibiotics should grow from $44.4 billion in 2020 to reach $65.4 billion by 2025 at a compound annual growth rate (CAGR) of 8.1% during the period of 2020-2025.

The global market for cell wall inhibitor antibiotic drugs segment should grow from $23.4 billion in 2020 to reach $35.1 billion by 2025 at a CAGR of 8.4% during the period of 2020-2025.

The global market for protein inhibitor antibiotic drugs segment should grow from $13.6 billion in 2020 to reach $20.2billion by 2025 at a CAGR of 8.3% during the period of 2020-2025.

Report Scope:

The report focuses on newer drugs and innovations in chemical compounds, vaccines and biologicals, recently launched or in development. Specifically excluded from the scope of research are vector or mosquito control approaches, strategies and products; drugs used for symptomatic treatment and not for the elimination of the virus from the host; and details on manufacturers and suppliers of non-branded generics. This report will also highlight the current and future market potentiality of antibiotics with detailed analysis of competitive environment between the companies. Drivers, restraints, opportunities, pricing analysis, impact of COVID-19, other infectious diseases and a regulatory scenario assessment will be covered in the current report. The report covers a market projection for 2025, and a market share for key players.

The report segments the market for antibiotics based on product type, route of administration, application and geography. Based on product type, the market is segmented into cell wall inhibitors, protein inhibitors, DNA inhibitors and other inhibitors (RNA, Mycolic Acid, Folic Acid). Based on route of administration, the market is segmented into oral and topical. The market is also presented based on application type, which is further segmented into human and veterinary.

By geography, the market has been segmented into the North America, Europe, Asia-Pacific, South America, and Middle East and Africa regions. Detailed analysis of major countries such as the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries and South Africa will be covered in the regional segment. For market estimates, data will be provided for 2019 as the base year, with estimates for 2020 and forecast value for 2025.

Report Includes:

  • 28 data tables and 16 additional tables
  • Comprehensive overview of the global market for antibiotics within the pharmaceutical industry
  • Analyses of the global market trends, with data corresponding to market size for 2018-2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
  • Latest information on market growth drivers and opportunities, industry supply chain structure, regulatory developments, technological advancements, and demographic shifts shaping the overall antibiotics marketplace
  • Evaluation of market growth during the forecast period, and deep dive of market share analysis data basis of product type, product, route of administration, end-user and geographical region
  • Country specific data and analysis for the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries and South Africa
  • Impact of COVID-19 on the pharmaceutical market for antibiotics and an outlook of short-term vs. long-term impacts of COVID-19 pandemic
  • Identification of the companies best positioned to meet the global market demand for antibiotic drugs on the basis of their proprietary technologies, M&A deals, collaborations, JVs and other strategic alliances
  • Detailed company profiles of the major global corporations, including Abbott, F. Hoffmann-La Roche AG, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Pfizer and Sanofi

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

  • Overview of Antibiotics
  • Common Side Effects of Antibiotics
  • Classification of Antibiotics
  • Cell Wall Inhibitors
  • Protein Inhibitors
  • DNA Inhibitors
  • Other Antibiotic Classes
  • Overview of Gram-negative and Gram-positive Bacteria
  • Route of Administration
  • Trends in the Market for Antibiotics
  • Funding for New Antibiotic Development
  • Increasing Focus on Antibiotic Drug Development by Smaller Pharmaceutical Firms
  • Growing Public-Private Partnerships

Chapter 4 Market Dynamics

  • Market Drivers
  • Growth of the Global Pharmaceutical Market Driven by Antibiotics
  • Rise in Geriatric Population and Infection Rate
  • Increasing Prevalence of Hospital-acquired Infections
  • Improved Awareness about Diseases and their Antibiotics
  • Market Restraints
  • Antibiotic-resistant Infections
  • Genericization of Antibiotics and Drugs
  • Declining Research and Development (R&D) Investment
  • Side Effects of Antibiotics
  • Market Opportunities
  • Market Expansion into Emerging Countries
  • Development of Novel Antibacterial Agents

Chapter 5 Market Breakdown by Product

  • Global Market for Antibiotics by Product
  • Cell Wall Inhibitors
  • Protein Inhibitors
  • DNA Inhibitors
  • Other Types of Inhibitors

Chapter 6 Market Breakdown by Route of Administration

  • Global Market for Antibiotics by Route of Administration
  • Oral Antibiotics
  • Topical Antibiotics
  • Other Routes of Administration

Chapter 7 Market Breakdown by Region

  • Global Market for Antibiotics by Region
  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Chapter 8 Impact of COVID-19 on the Pharmaceutical Industry

  • Short-term Impact
  • Change in Demand
  • Shift of Communication and Promotions to Remote Interactions
  • Research and Development Changes
  • Long-term Impact
  • Delayed Approvals for Non-COVID-related Pharmaceutical Products
  • Self-sufficiency in Pharma Industry
  • Pharmaceutical Industry Growth Slow-Down
  • Changes in Consumption Trends in Health-related Products

Chapter 9 Clinical Developments and Pipeline Products

  • Respiratory Tract Infections

Chapter 10 Value Chain Analysis

  • Introduction
  • China is a Becoming a Center of Microbial Threats

Chapter 11 Regulatory Scenario

  • FDA and International Regulation
  • Recent Regulatory Reforms
  • Ketek Case Study

Chapter 12 Competitive Landscape

  • Global Company Market Share Analysis
  • Mergers, Collaborations, Partnerships and Acquisitions

Chapter 13 Company Profiles

  • ABBOTT
  • F. HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • JOHNSON & JOHNSON
  • MERCK & CO., INC.
  • MYLAN N.V.
  • PFIZER INC.
  • SANOFI

Chapter 14 Appendix: Acronyms

List of Tables

  • Summary Table A : Global Market for Antibiotics, by Product, Through 2025
  • Summary Table B : Global Market for Antibiotics, by Route of Administration, Through 2025
  • Table 1 : Major Differences Between Gram-positive and Gram-negative Organisms
  • Table 2 : Proportion of Resistant Strains, by WHO Region
  • Table 3 : Global Market for Antibiotics, by Product, Through 2025
  • Table 4 : Global Market for Cell Wall Inhibitors, by Region, Through 2025
  • Table 5 : Global Market for Protein Inhibitors, by Region, Through 2025
  • Table 6 : Global Market for DNA Inhibitors, by Region, Through 2025
  • Table 7 : Global Market for Other Types of Inhibitors, by Region, Through 2025
  • Table 8 : Global Market for Antibiotics, by Route of Administration, Through 2025
  • Table 9 : Global Market for Oral Antibiotics, by Region, Through 2025
  • Table 10 : Global Market for Topical Antibiotics, by Region, Through 2025
  • Table 11 : Global Market for Other Routes of Administration of Antibiotics, by Region, Through 2025
  • Table 12 : Global Market for Antibiotics, by Region, Through 2025
  • Table 13 : North American Market for Antibiotics, by Product, Through 2025
  • Table 14 : North American Market for Antibiotics, by Route of Administration, Through 2025
  • Table 15 : North American Market for Antibiotics, by Country, Through 2025
  • Table 16 : European Market for Antibiotics, by Product, Through 2025
  • Table 17 : European Market for Antibiotics, by Route of Administration, Through 2025
  • Table 18 : European Market for Antibiotics, by Country, Through 2025
  • Table 19 : Asia-Pacific Market for Antibiotics, by Product, Through 2025
  • Table 20 : Asia-Pacific Market for Antibiotics, by Route of Administration, Through 2025
  • Table 21 : Asia-Pacific Market for Antibiotics, by Country, Through 2025
  • Table 22 : Latin American Market for Antibiotics, by Product, Through 2025
  • Table 23 : Latin American Market for Antibiotics, by Route of Administration, Through 2025
  • Table 24 : Latin American Market for Antibiotics, by Country, Through 2025
  • Table 25 : Middle Eastern and African Market for Antibiotics, by Product, Through 2025
  • Table 26 : Middle Eastern and African Market for Antibiotics, by Route of Administration, Through 2025
  • Table 27 : Middle Eastern and African Market for Antibiotics, by Country, Through 2025
  • Table 28 : Antibiotics and Combinations in Global Clinical Development and the Pipeline
  • Table 29 : FDA-Approved Antibacterial Drugs, 2018
  • Table 30 : FDA-Approved Antibacterial Drugs, 2019
  • Table 31 : Abbott: Antibiotics Product Portfolio
  • Table 32 : F. Hoffmann-La Roche AG: Antibiotics Product Portfolio
  • Table 33 : GlaxoSmithKline Plc: Antibiotics Product Portfolio
  • Table 34 : Johnson & Johnson: Antibiotics Product Portfolio
  • Table 35 : Merck & Co., Inc.: Antibiotics Product Portfolio
  • Table 36 : Merck & Co., Inc.: Antibiotic Drugs Overview
  • Table 37 : Mylan N.V.: Antibiotics Product Portfolio
  • Table 38 : Pfizer Inc.: Antibiotics Product Portfolio
  • Table 39 : Pfizer Inc.: Antibiotic Drugs Overview
  • Table 40 : Sanofi: Antibiotics Product Portfolio
  • Table 41 : Sanofi S.A.: Antibiotic Drugs Overview
  • Table 42 : Acronyms Used in this Report

List of Figures

  • Summary Figure A : Global Market Shares of Antibiotics, by Product, 2019
  • Summary Figure B : Global Market Shares of Antibiotics, by Route of Administration, 2019
  • Figure 1 : Share of API Manufacturing Facilities for All Drugs, by Country/Region, August 2019
  • Figure 2 : Share of Population Aged 65 Years or Over, by Region, 2019
  • Figure 3 : Forecasted Share of Population Aged 65 Years or Over, by Region, 2050
  • Figure 4 : Increase in Aging Population, 2011 and 2050
  • Figure 5 : Distribution of Population with HAIS in the U.S., 2014
  • Figure 6 : Major Socioeconomic and Political Factors Contributing to Antibiotic Resistance
  • Figure 7 : Global Market Shares of Antibiotics, by Product, 2019
  • Figure 8 : Global Market for Cell Wall Inhibitors, 2018-2025
  • Figure 9 : Global Market Shares of Antibiotics, by Cell Wall Inhibitor, 2019
  • Figure 10 : Global Market for Cell Wall Inhibitors, by Region, 2018-2025
  • Figure 11 : Global Market for Protein Inhibitors, 2018-2025
  • Figure 12 : Global Market Shares of Antibiotics, by Protein Inhibitor, 2019
  • Figure 13 : Global Market for Protein Inhibitors, by Region, 2018-2025
  • Figure 14 : Global Market for DNA Inhibitors, 2018-2025
  • Figure 15 : Global Market Shares of Antibiotics, by DNA Inhibitor, 2019
  • Figure 16 : Global Market for DNA Inhibitors, by Region, 2018-2025
  • Figure 17 : Global Market for Other Types of Inhibitors, 2018-2025
  • Figure 18 : Global Market for Other Types of Inhibitors, by Region, 2018-2025
  • Figure 19 : Global Market Shares of Antibiotics, by Route of Administration, 2019
  • Figure 20 : Global Market for Oral Antibiotics, 2018-2025
  • Figure 21 : Global Market for Oral Antibiotics, by Region, 2018-2025
  • Figure 22 : Global Market for Topical Antibiotics, 2018-2025
  • Figure 23 : Global Market for Topical Antibiotics, by Region, 2018-2025
  • Figure 24 : Global Market for Other Routes of Administration of Antibiotics, 2018-2025
  • Figure 25 : Global Market for Other Routes of Administration of Antibiotics, by Region, 2018-2025
  • Figure 26 : Global Market Shares of Antibiotics, by Region, 2019
  • Figure 27 : North American Market Shares of Antibiotics, by Product, 2019
  • Figure 28 : North American Market Shares of Antibiotics, by Cell Wall Inhibitor, 2019
  • Figure 29 : North American Market Shares of Antibiotics, by Protein Inhibitor, 2019
  • Figure 30 : North American Market Shares of Antibiotics, by DNA Inhibitor, 2019
  • Figure 31 : North American Market Shares of Antibiotics, by Route of Administration, 2019
  • Figure 32 : North American Market Shares of Antibiotics, by Country, 2019
  • Figure 33 : U.S. Market for Antibiotics, 2018-2025
  • Figure 34 : Canadian Market for Antibiotics, 2018-2025
  • Figure 35 : Mexican Market for Antibiotics, 2018-2025
  • Figure 36 : European Market Shares of Antibiotics, by Product, 2019
  • Figure 37 : European Market Shares of Antibiotics, by Cell Wall Inhibitor, 2019
  • Figure 38 : European Market Shares of Antibiotics, by Protein Inhibitor, 2019
  • Figure 39 : European Market Shares of Antibiotics, by DNA Inhibitor, 2019
  • Figure 40 : European Market Shares of Antibiotics, by Route of Administration, 2019
  • Figure 41 : European Market Shares of Antibiotics, by Country, 2019
  • Figure 42 : German Market for Antibiotics, 2018-2025
  • Figure 43 : French Market for Antibiotics, 2018-2025
  • Figure 44 : U.K. Market for Antibiotics, 2018-2025
  • Figure 45 : Italian Market for Antibiotics, 2018-2025
  • Figure 46 : Spanish Market for Antibiotics, 2018-2025
  • Figure 47 : Rest of the European Market for Antibiotics, 2018-2025
  • Figure 48 : Asia-Pacific Market Shares of Antibiotics, by Product, 2019
  • Figure 49 : Asia-Pacific Market Shares of Antibiotics, by Cell Wall Inhibitor, 2019
  • Figure 50 : Asia-Pacific Market Shares of Antibiotics, by Protein Inhibitor, 2019
  • Figure 51 : Asia-Pacific Market Shares of Antibiotics, by DNA Inhibitor, 2019
  • Figure 52 : Asia-Pacific Market Shares of Antibiotics, by Route of Administration, 2019
  • Figure 53 : Asia-Pacific Market Shares of Antibiotics, by Country, 2019
  • Figure 54 : Japanese Market for Antibiotics, 2018-2025
  • Figure 55 : Chinese Market for Antibiotics, 2018-2025
  • Figure 56 : Indian Market for Antibiotics, 2018-2025
  • Figure 57 : Australia and New Zealand Market for Antibiotics, 2018-2025
  • Figure 58 : Rest of Asia-Pacific Market for Antibiotics, 2018-2025
  • Figure 59 : Latin American Market Shares of Antibiotics, by Product, 2019
  • Figure 60 : Latin American Market Shares of Antibiotics, by Cell Wall Inhibitor, 2019
  • Figure 61 : Latin American Market Shares of Antibiotics, by Protein Inhibitor, 2019
  • Figure 62 : Latin American Market Shares of Antibiotics, by DNA Inhibitor, 2019
  • Figure 63 : Latin American Market Shares of Antibiotics, by Route of Administration, 2019
  • Figure 64 : Latin American Market Shares of Antibiotics, by Country, 2019
  • Figure 65 : Brazilian Market for Antibiotics, 2018-2025
  • Figure 66 : Argentinian Market for Antibiotics, 2018-2025
  • Figure 67 : Rest of Latin American Market for Antibiotics, 2018-2025
  • Figure 68 : Middle Eastern and African Market Shares of Antibiotics, by Product, 2019
  • Figure 69 : Middle Eastern and African Market Shares of Antibiotics, by Cell Wall Inhibitor, 2019
  • Figure 70 : Middle Eastern and African Market Shares of Antibiotics, by Protein Inhibitor, 2019
  • Figure 71 : Middle Eastern and African Market Shares of Antibiotics, by DNA Inhibitor, 2019
  • Figure 72 : Middle Eastern and African Market Shares of Antibiotics, by Route of Administration, 2019
  • Figure 73 : Middle Eastern and African Market Shares of Antibiotics, by Country, 2019
  • Figure 74 : Market for Antibiotics in the GCC Countries, 2018-2025
  • Figure 75 : South African Market for Antibiotics, 2018-2025
  • Figure 76 : Rest of Middle Eastern and African Market for Antibiotics, 2018-2025
  • Figure 77 : Impact of COVID-19 on the Pharmaceutical Industry
  • Figure 78 : Global Market Shares of Antibiotics, by Manufacturer, 2019
  • Figure 79 : Abbott: Annual Revenue, 2016-2019
  • Figure 80 : Abbott: Revenue Shares, by Country/Region, 2019
  • Figure 81 : Abbott: Revenue Shares, by Business Unit, 2019
  • Figure 82 : F. Hoffmann-La Roche AG: Annual Revenue, 2016-2019
  • Figure 83 : F. Hoffmann-La Roche AG: Revenue Shares in Pharmaceutical Segment, by Country/Region, 2019
  • Figure 84 : F. Hoffmann-La Roche AG: Revenue Shares, by Business Segment, 2019
  • Figure 85 : GlaxoSmithKline Plc: Annual Revenue, 2016-2019
  • Figure 86 : GlaxoSmithKline Plc: Revenue Shares, by Pharmaceuticals, 2019
  • Figure 87 : Johnson & Johnson: Annual Revenue, 2016-2019
  • Figure 88 : Johnson & Johnson: Revenue Shares, by Region, 2019
  • Figure 89 : Johnson & Johnson: Revenue Shares, by Business Unit, 2019
  • Figure 90 : 90Merck & Co., Inc.: Annual Revenue, 2016-2019
  • Figure 91 : Merck & Co., Inc.: Revenue Shares, by Region, 2019
  • Figure 92 : Merck & Co., Inc.: Revenue Shares, by Business Unit, 2019
  • Figure 93 : Mylan N.V.: Annual Revenue, 2016-2019
  • Figure 94 : Mylan N.V.: Revenue Shares, by Region, 2019
  • Figure 95 : Mylan N.V.: Revenue Shares, by Business Unit, 2019
  • Figure 96 : Pfizer Inc.: Annual Revenue, 2016-2019
  • Figure 97 : Pfizer Inc.: Revenue Shares, by Country/Region, 2019
  • Figure 98 : Pfizer Inc.: Revenue Shares, by Business Segment, 2019
  • Figure 99 : Sanofi: Annual Revenue, 2016-2019
  • Figure 100 : Sanofi: Revenue Shares, by Region/Country, 2019
  • Figure 101 : Sanofi: Revenue Shares, by Business Segment, 2019